Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor. P276-00 exhibited significant tumour
reduction in animal models with less adverse effects.Based on the results from various
in-vitro studies, P276-00 could be a potential candidate as a new mechanism based drug for
the treatment of cancer.This Phase I study will determine the Maximum Tolerated Dose,Dose
Limiting Toxicity and efficacy of P 276-00 in patients with advanced Refractory neoplasms.